Abvc Biopharma (ABVC) Tax Provisions (2016 - 2026)
Abvc Biopharma's (ABVC) quarterly Tax Provisions came in at -$354887.0 in Q1 2026, down 79.17% YoY from -$1.7 million in Q1 2025, and down 67440.99% on a QoQ basis from $527.0 in Q3 2025.
Abvc Biopharma (ABVC) Tax Provisions (2016 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 11 years of Tax Provisions data on file, last reported at -$354887.0 in Q1 2026.
- Quarterly Tax Provisions fell 79.17% year-over-year to -$354887.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$330733.0 (down 7.17% YoY) and the FY2025 annual result came in at $24154.0, up 121.85% from the prior year.
- Tax Provisions declined to -$354887.0 in Q1 2026, from $527.0 in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $796178.0 in Q4 2022 to a low of -$354887.0 in Q1 2026.
- A 5-year average of $19057.3 and a median of $355.0 in 2024 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2023 — Tax Provisions surged 199.08% — and 2024, when it tumbled 235.74%.
- Tracing ABVC's Tax Provisions over 5 years: stood at $796178.0 in 2022, then plunged by 77.98% to $175310.0 in 2023, then tumbled by 99.8% to $355.0 in 2024, then jumped by 48.45% to $527.0 in 2025, then sank by 67440.99% to -$354887.0 in 2026.
- The last three Tax Provisions figures came in at -$354887.0 (Q1 2026), $527.0 (Q3 2025), and $23627.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - | -170,201.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -170,201.00 |
| Mar 31, 2026 | -354,887.00 |
| Sep 30, 2025 | 527.00 |
| Jun 30, 2025 | 23,627.00 |
| Mar 31, 2025 | -198,071.00 |
| Sep 30, 2024 | 355.00 |
| Jun 30, 2024 | -110,894.00 |
| Dec 31, 2023 | 175,310.00 |
| Sep 30, 2023 | -999.00 |
| Jun 30, 2023 | 81,695.00 |
| Dec 31, 2022 | 796,178.00 |
| Sep 30, 2022 | 4,222.00 |
| Jun 30, 2022 | -82,451.00 |
| Mar 31, 2022 | -86,867.00 |
| Dec 31, 2021 | 1.01 Mn |
| Sep 30, 2021 | -75,667.00 |
| Jun 30, 2021 | -59,564.00 |
| Mar 31, 2021 | -51,024.00 |
| Dec 31, 2020 | -86,405.00 |
| Sep 30, 2020 | -44,735.00 |